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1. Introduction 
Tuberculosis (TB) is still one of the major causes of bacterial infections and mortality in the 
world. In 1944, streptomycin was introduced as a first antibiotic remedy to cure TB 
effectively. After that, in the 1940s and 50s, with the introduction of pyrazinamide (PZA), 
rifampicin (RIF), isoniazid (INH), ethambutol and streptomycin as well as cocktail-drug 
treatment of tuberculosis, a cure for tuberculosis was considered reasonable. This period 
was a period of optimism, as it was believed that TB could be cured and eliminated. Hence, 
the United Nations targeted elimination of TB by 2025. These expectations were dashed as a 
worldwide pandemic of tuberculosis began in 1987 and the World Health Organization 
declared that tuberculosis posed a global emergency in 1993. The estimates of the global 
burden of the disease caused by Mycobacterium tuberculosis in 2009 are as follows: 9.4 million 
incident cases, 14 million prevalent cases, 1.3 million deaths among HIV-negative people 
and 0.38 million deaths among HIV-positive people. It is estimated that among TB patients 
notified in 2009, 250 000 had multidrug resistant TB (MDR-TB). The situation is worsening 
because of the increasing incidence of single-drug resistant, multidrug resistant and 
extensively drug-resistant (XDR-TB) TB (WHO report, 2010; The Stop TB Partnership, 2010; 
Velayati et al., 2009). This chapter deals with pyrazinecarboxamide (amide of 
pyrazinecarboxylic acid, PZA, see Fig. 1, structure I) and its derivatives. PZA was 
introduced to clinical practice in 1952, and it has been among the first-line antituberculosis 
(anti-TB) drugs (Kushner et al., 1952; Solotorovsky, 1952; Steele & Des Prez, 1988). 
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Fig. 1. Hydrolysis of pyrazinamide (PZA, I) to pyrazinoic acid (POA, II). 
PZA is an important component in the intensive phase of short-course treatment of TB 
owing to its sterilizing effect, ability to act in acidic environments and excellent synergy 
with rifampicin (Zhang & Mitchison, 2003). PZA exhibits stringent structure-activity 
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relationships (SAR) requiring the pyrazine ring and the carboxamide moiety (for more 
details see Section 2.3) for antimycobacterial activity. Pyrazine is a 6π-electron-deficient 
heteroaromatic compound, in which the inductive effects of the nitrogen atoms induce a 
partially positive charge on the carbon atoms. Pyrazine, its derivatives as well as other 
1,4-diazines, i.e. compounds with partial pyrazine structure (e.g. quinoxaline, phenazine, 
pteridine, flavin and their derivatives), demonstrate unique physico-chemical properties 
that are caused by a low lying unoccupied π-molecular orbital and by the ability to act as a 
bridging ligand. Pyrazine and derivatives are known to provide a superexchange pathway 
for magnetic exchange (Awwadi et al., 2005). Due to these two properties 1,4-diazines, and 
especially their parent compound pyrazine, possess a characteristic reactivity. A fully 
comprehensive study of the pyrazines including reactivity and synthesis is beyond the 
scope of this work but can be found in the literature (Bird, 1992; Brown, 2002; Joule & Mills, 
2010). Pyrazines are a class of compounds that occur almost ubiquitously in nature. Their 
effectiveness at very low concentrations and the ever increasing application of synthetic 
pyrazines in the flavour and fragrance industry and in the food and pharmaceutical 
industries are responsible for the high interest in these compounds (Doležal, 2006a). 
Tetramethylpyrazine (ligustrazine) was discovered as a natural product and is reported to 
scavenge the superoxide anion and decrease nitric oxide production in human 
polymorphonuclear leukocytes (Zhang, 2003). In plants or insects, pyrazines play the roles 
of attractants, pheromones and signal substances. Similar substances were found in food, 
and therefore their sensoric properties were investigated (Maga, 1992; Wagner et al., 1999). 
Mutagenic/carcinogenic pyrazines were found in processed foods, smoked-dried bonito 
meat, roasted coffee beans and charred eggs (Kikugawa, 2004). Synthetic pyrazines are used 
as “identical” additives in the food manufacturing and tobacco industries (Maga, 1992). 
Pyrazines are also synthesized by a number of fungi, such as the antibiotic aspergillic acid 
(White & Hill, 1943; Micetich & MacDonald, 1965) and the fungicidal pigment 
pulcherriminic acid (MacWilliam, 1959; MacDonald, 1965; Uffen Canole-Parola, 1972). The 
pyrazine derivative coelenterazine was found in many marine bioluminescent organisms 
(Thompson & Rees, 1994). Other marine pyrazine alkaloids botryllazines A and B isolated 
from the red ascidian Botryllus leachi possess interesting cytotoxic properties (Duran et al., 
1999). The wide occurrence of pyrazines in nature has been already discussed (Woolfson & 
Rothschild, 1990; Müller & Rappert, 2010; Rajini et al., 2011). Pyrazines are also very 
important anthropogenic compounds, especially dihydropyrazines are essential for all 
forms of life due to their DNA strand-breakage activity and/or due to their influence on 
apoptosis (Yamaguchi, 2007). It is not surprising that many simple pyrazines have potent 
pharmaceutical activities. Examples are antiviral drugs flutimide (Singh & Tamassini, 2001), 
favipiravir (Furuta et al., 2009), the potential antineoplastic pyrazinediazohydroxide 
(Edelman et al., 1998) or acipimox, a niacin analogue used as a hypolipidemic agent 
(Ambrogi et al., 1980). The introduction of the pyrazine ring in bulky compounds brings 
specific chemical and physico-chemical properties for the whole molecule, like some weak 
basicity and aromatic character, examples are the antibacterial sulfonamide sulfadiazine 
(Roblin et al., 1940) or the second-generation sulfonylurea derivative with hypoglycaemic 
activity glipizide (Ambrogi, 1972). Such type of modification can be also found in the 
proteasome inhibitor for the treatment of multiple myeloma bortezomib (Adams, 1996), in 
the fentanyl derivative with selectivity for the μ opioid receptor mirfentanil (France et al., 
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1991), in the drug for smoking cessation varenicline (Coe, 2005) or in the protease inhibitor 
for treatment of hepatitis C telaprevir (Furuta et al., 2009). Another examples are the diuretic 
amiloride and its derivative (Cragoe et al., 1964) newly also used for the treatment of cystic 
fibrosis, elpetrigine, a new chemical entity that combines two mechanisms known to work 
well in antiepileptic drugs (it is both a sodium channel and calcium channel blocker) 
(Foreman et al., 2008), and eszopiclone, a short acting nonbenzodiazepine sedative hypnotic 
(Cotrel et al., 1975). Diallylsulfide (a component of Allium sativum) has chemoprotective 
activity and pyrazine has binding affinity to cytochrome P-450 2E1 (inhibits CYP 2E1 
activity), therefore, pyrazine was attached to the allylsulfide radical of diallylsulfide to form 
2-allylsulfanylpyrazine to increase the binding affinity of diallylsulfide to CYP 2E1 (Kim et 
al., 1997). A similar pyrazine derivative, oltipraz, is an antischistosomal agent and a 
chemoprotective agent increasing the level of glutathione-S-transferases (Clapper, 1998). 
From this point of view the pyrazine ring can be an important part of peptide-mimicking 
molecules to modulate the interactions between proteins and a drug. The importance of the 
pyrazine (1,4-diazine) ring for biological activity can be evaluated primarily from the point 
of view of the molecular size/space and its physico-chemical properties. In relatively small 
compounds, the pyrazine ring is necessary for biological action due to its resemblance 
(bioisosterism) to the naturally occurring compounds (in human), for example, nicotinamide 
or anticancer and antiviral drugs containing the 1,4-diazine ring as position analogues of 
pyrimidine (1,3-diazine) nucleic bases (Doležal, 2006a). 
Three main types of mycobacterial population are found in a patient with active TB, 
(i) actively growing bacilli, (ii) slowly growing bacilli inside macrophages, and (iii) the 
persisting semidormant bacilli localised extracellularly in solid caseous lesions. Since the pH 
is acidic inside the macrophages, PZA is the most active drug acting on this population 
followed by RIF, both drugs have crucial role in achieving sterilization (Mitchison, 1985; 
Zhang & Mitchison, 2003). While TB is curable, MDR-TB and XDR-TB may be fatal and the 
cure rates are frustratingly low. For this purpose, it is necessary to accelerate investigations 
to identify new types of anti-TB drugs acting on novel drug targets (Vinšová & Krátký, 
2010). 
2. Pyrazinamide 
PZA (see Fig. 1, structure I) is indicated for the initial treatment of active tuberculosis in 
adults and children when combined with other anti-TB agents. PZA is an important 
sterilising tuberculosis drug that helps to shorten the duration of current chemotherapy 
regimens for tuberculosis. It is unique among antituberculosis drugs in having no genomic 
site of action and having greater bactericidal activity as bacillary metabolism slows down; it 
is remarkably effective in human disease. PZA is an important component in the intensive 
phase of short-course treatment of TB owing to its sterilising activity, ability to work in 
acidic environments (in macrophages), and excellent synergy with RIF (Mitchison, 1985; 
Zhang & Mitchison, 2003). Pyrazinamide appears to kill at least 95% of the semi-dormant 
bacterial population persisting in a low-pH environment since its activity is present only in 
the acidic environment found in active inflammation (Mitchison, 1985; Heifets et al., 1992). 
The development of a new drug with a similar mode of activity might be very fruitful, 
especially if there were no need for an acid environment (Aldrich et al., 2010). Objectives for 
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TB drug development are: (i) to shorten the total duration of effective treatment and/or 
significantly reduce the total number of doses needed to be taken under directly observed 
treatment, short-course (DOTS) supervision, (ii) to improve the treatment of MDR-TB, 
which cannot be treated with INH and RMP, and (iii) to provide a more effective treatment 
of latent TB infection (LTBI). Genomics, the systematic identification of all of the genes in a 
cell through deoxyribonucleic acid (DNA) sequencing and bioinformatic analysis, also offers 
great potential in terms of drug target discovery and development of new antibacterial 
agents, and the recently sequenced genome of M. tuberculosis should provide a number of 
new targets for novel drugs (Cole et al., 1998; Vinšová & Krátký, 2011). 
2.1 Metabolism and toxicity of PZA 
Pyrazine is a weak diacid base (pK1 = 0.57; pK2 = -5.51), weaker than pyridine (pyrazine 
pKa = 1.1, pyridine pKa = 5.2) due to the induction effect of the second nitrogen. The 
absorption of weak amine bases such as pyrazine derivatives is optimal at intestinal pH (5–7). 
In humans and laboratory rodents, orally administered substituted pyrazines are rapidly 
absorbed from the gastrointestinal tract and excreted. Methyl-substituted pyrazines are 
oxidized to yield the corresponding pyrazine-2-carboxylic acids. Pyrazine-2-carboxylic acid 
derivatives and 5-hydroxypyrazine-2-carboxylic acid derivatives are major urinary 
metabolites formed by side-chain oxidation and ring hydroxylation of alkyl-substituted 
pyrazine derivatives. PZA is hydrolyzed to pyrazine-2-carboxylic acid in humans and 
laboratory animals, while in other animals it can be metabolised also to 5-hydroxypyrazine-
2-carboxylic acid (Sak-Bosnar & Kovar, 2005). 
Early clinical studies described an unacceptable incidence of hepatotoxicity, but PZA exerts 
minimal toxicity when used for brief periods (preferably in six-month regimens) (Steele & 
Des Prez, 1988). The most frequent side effect is nongouty polyarthralgia (Zierski & Bek, 
1980), and the phototoxicity of PZA has been described recently (Vargas et al., 2003). 
2.2 Mechanism of action of PZA 
The mode of action of PZA is unusual and has confused scientists for decades since the 
discovery of its antimycobacterial activity in 1952. The main reason is that PZA is 
completely different from common antibacterial chemotherapeutics that are primary active 
against growing bacteria, since PZA has no apparent activity against growing tubercle 
bacilli at neutral pH. PZA plays a unique role in shortening the therapy from 9–12 months to 
6 months, because it kills a population of dormant/semi-dormant tubercle bacilli that are 
not killed by other antituberculous drugs (Mitchison, 1985). The basic knowledge about the 
mechanism of action of PZA was very poor for a long time. PZA as a prodrug form of 
pyrazinecarboxylic acid (pyrazinoic acid, POA, see Fig. 1, structure II) is devoid of 
significant antibacterial activity. PZA is activated in the mycobacterial cell by 
pyrazinamidase (PncA) and/or nicotinamidase (Konno et al., 1967), while its action is 
focused on depletion of membrane energy. Mycobacterial amidase, pyrazinamidase or 
nicotinamidase (nicotine deamidase, NAMase, EC 3.5.1.19), catalyzes the conversion of PZA 
to POA and nicotinamide to nicotinic acid (niacin) (Tarnok et al., 1979). POA is only active 
under acidic conditions (McDermott & Tompsett, 1954; Yamamoto et al., 1995). The cell 
envelope of M. tuberculosis, a Gram-positive bacterium with a G+ C-rich genome, contains 
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an additional layer beyond the peptidoglycan that is exceptionally rich in unusual free 
lipids, glycolipids and polysaccharides (Kolattukudy et al., 1997). The biosynthetic 
pathways generate cell-wall components such as mycolic acids, mycocerosic acid, 
phenolthiocerol, lipoarabinomannan and arabinogalactan, and several of these may 
contribute to mycobacterial longevity, trigger inflammatory host reactions and act in 
pathogenesis. The complete genome sequence of the strain M. tuberculosis H37Rv was 
determined (Cole et al., 1998). Although 40% of protein-coding genes were functionally 
annotated based on sequence similarity analysis and other analysis methods, 60% of them 
were reported as unknown functions (Manabe et al., 2000). This situation was improved in 
2002 by Camus et al., who re-annotated M. tuberculosis’s genome (Camus, 2002). Mycolic 
acid is the major constituent of the unique mycobacterial cell wall, which comprises 
arabinogalactan-mycolate covalently linked with peptidoglycan and trehalose dimycolate 
and protects the tubercle bacillus from general antibiotics and from the host’s immune 
system. 
  
Fig. 2. Mode of action of PZA. The first-line antituberculosis drug PZA interferes with cell 
wall biosynthesis in M. tuberculosis. PZA is a prodrug and is converted to an active form 
(POA) by a nicotinamidase-peroxidase enzyme known as pyrazinamidase (PncA). POA 
inhibits the action of FAS I and FAS II. FAS I is involved in the synthesis of short-chain 
mycolic acids, and FAS II is involved in the synthesis of longer chains. Mycolic acids are 
essential structural components of the mycobacterial cell wall and are attached to the 
arabinogalactan layer. (Taken from Immunopeadia.org/First-Line Therapeutic Drugs in 
<http://www.immunopaedia.org.za/fileadmin/gallery/TB%20Drugs%20-%20Line/ 
pyrazinamide.jpg> with the permission of the Research Administrator of the website.) 
The synthesis of mycolic acids has been shown to be critical for the survival of 
M. tuberculosis; therefore, the mycolic acid pathway (MAP) has been of great interest as 
indicated by a large number of biochemical and genetic studies in the literature. The 
differences in the composition of free lipids at the cell envelope surface may result in 
strain-specific M. tuberculosis-Homo sapiens interplay modalities that contribute to 
determination of outcomes of the initial pathogen-host encounters as well as the infection 
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and disease course (Crick et al., 2008). Large fatty acids constitute a significant proportion of 
the mass of the cell wall core (see Fig. 2), forming a hydrophobic permeability barrier (Liu et 
al., 1996). The endogenous resistance of M. tuberculosis to many drugs (Brennan & Nikaido, 
1995; Liu et al., 1999) is generally attributed to the presence of the permeability barrier 
generated by the mycolic acids. At least two discrete types of the enzyme system, fatty acid 
synthase I (FAS I, EC 2.3.1.85) and fatty acid synthetase II (FAS II), are involved in fatty acid 
biosynthesis in mycobacteria. The fatty acids are elongated by repeated cycles using these 
enzymes; generally the FAS I system is responsible for shorter chains (up to C16–C26) and the 
FAS II system, for longer chains found in meromycolates (to C56) (Kolattukudy et al., 1997; 
Mdluli et al., 1998). 
As PZA is a prodrug, hydrolytic activation by pyrazinamidase (PncA) that converts it to 
POA is required (Scorpio & Zhang, 1996). It was assumed that POA has both specific and 
nonspecific effects due to an intracellular accumulation of the liberated acid. This 
accumulation lowers the intracellular pH to a suboptimal level that is likely to inactivate a 
vital target enzyme (Zhang & Mitchison, 2003). 
 
Fig. 3. Mode of action of PZA. PZA diffuses into M. tuberculosis in a passive transport, is 
converted into POA by PncA, and because of an inefficient efflux system, accumulates in 
huge amounts in the bacterial cytoplasm. (Ref. Wade & Zhang, 2004; reprinted with the 
editor's permission). 
As pKa of POA is 2.9, close to neutral intracellular pH, POA will be in the anion form and 
will be transported out of the cell through passive diffusion and deficient efflux to the cell 
surface (see Fig. 3). Under acidic pH, POA anion will form protonated or uncharged HPOA, 
which will diffuse back into the cell. The acid-facilitated POA influx is stronger than the 
weak POA efflux and this causes accumulation of POA in M. tuberculosis (Scorpio & Zhang, 
1996). As HPOA enters the bacilli at acid pH, it brings in protons and over time could cause 
acidification of the cytoplasm and disruption of the proton motive force and depletion of 
energy. The disruption of proton motive force by POA then inhibits the membrane transport 
function. PZA acts as an ionophore, causing cellular acidification (Hurdle et al., 2011). 
Patient isolates that are resistant to PZA typically show mutation within the gene encoding 
PncA (Scorpio & Zhang, 1996). Some weak acids (benzoic, sorbic and propyl 
hydroxybenzoic acid), UV and various energy inhibitors were found to enhance the activity 
of PZA in vitro against M. tuberculosis (Wade & Zhang, 2006). 
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Raman et al. applied a systems-based approach, Flux Balance Analysis (FBA), to investigate 
the MAP of M. tuberculosis H37Rv for identification of antituberculosis drug targets in 2005 
(Raman et al., 2005). The MAP model consists of four sub-pathways: (i) production of 
malonyl CoA, (ii) FAS I pathway, (iii) FAS II pathway and (iv) condensation of FAS I and 
FAS II products into methoxy- and keto-mycolic acids. 
2.3 Modifications of PZA structure 
The PZA and POA as potential analeptic drugs were synthesized in Germany (Dalmer & 
Eugen, 1936) and later in USA as intermediate compounds on the pathway of aminopyrazine 
synthesis (Hall & Spoerri, 1940), but the antimycobacterial activity of PZA was reported later, 
in 1952. The use of nicotinamide-related compounds for the therapy of tuberculosis followed 
the serendipitous observation that nicotinamide was effective for the treatment of murine 
tuberculosis (Chorine et al., 1945; McKenzie et al., 1949). The initial information that 
nicotinamide possessed modest antitubercular activity stimulated the evaluation of other 
analogues. This observation led to the subsequent discovery of not only PZA but also INH 
(Vinšová et al., 2008) and ethionamide. Of many nicotinamide analogues that were 
subsequently synthesized and evaluated for antituberculosis activity, only PZA was active in 
vivo (Deassau et al., 1952; Yeager et al., 1952; Malone et al., 1952; Solotorovsky et al., 1952). In 
the same year (Kushner et al., 1952) the synthesis of 49 PZA derivatives and 14 related 
compounds was reported, and their antimycobacterial activities in the in vivo murine system 
were briefly referred to, but no information on their in vitro antimycobacterial activities was 
provided. It was soon shown that an enzyme called nicotinamidase inside the mycobacterium 
hydrolyzed nicotinamide and pyrazinamide to the corresponding carboxylic acids, and these 
carboxylic acids were the actual active compounds (Konno et al., 1967). However, nicotinic 
and pyrazinoic acids did not demonstrate activity due to their poor penetration into 
mycobacterial cells. PZA is still unusual because of its narrow spectrum of activity. Several 
aminomethylene analogues/prodrugs of PZA were prepared and evaluated including 
morphazinamide (see Fig. 4, structure III), which is a morpholine derivative, Mannich base of 
PZA (Felder & Tiepolo, 1962); the lack of any demonstrable improvement over PZA in vivo led 
to its abandonment. Surprisingly, it was found that amides of 5-substituted pyrazinoic acid 
displayed good activity against M. avium, PZA-resistant M. tuberculosis, and phagocytized M. 
tuberculosis, and these compounds also showed activity over a broad range of pH values 
(Heifets et al., 1986). M. avium became a serious cause of disseminated infection among 
patients with AIDS. Novel aminomethylene analogues of PZA (see Fig. 4, general structure IV) 
were tested (Chung et al., 2008). The activity of N-(pyrrolidin-1-ylmethyl)pyrazine-2-
carboxamide was higher than that of PZA when administered with rifalazil or RIF in a mouse 
model of infection. The activity of these analogues against PZA-resistant strains suggests that 
development of the second generation PZA analogues may be especially fruitful. 
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Fig. 4. Structures of aminomethylene analogues of PZA. 
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PZA exhibits remarkably stringent structure-activity relationships (SAR) demonstrating 
an absolute requirement for the pyrazine nucleus and the carboxamide moiety in position 
2 for the activity. The modifications of the pyrazine ring with pyridazine and/or 
pyrimidine were not successful (Rodgers et al., 1952). It can be concluded that any 
isosteric replacement of carbon by nitrogen or shift of nitrogen to another position results 
in the loss of antimycobacterial activity. Also ortho-condensation of the 
aromatic/heteroaromatic ring with pyrazine nucleus did not lead to active compounds. 
Similarly, the substitution of the carboxamide group in thioamide, N-methyl, N-acetyl, 
hydrazide (analogy with INH), nitrile, tetrazole and free carboxylic acid provided 
compounds that were completely inactive in vivo (Kushner et al., 1952). One of the 
effective methods that can lead to new drug discovery is the bioisosteric replacement of a 
functional group. Numerous functional groups have been reported as bioisosteric 
replacements for the carboxylic acid functionality (Thornber, 1979). The prodrug approach 
in series of PZA derivatives is already very hopeful. Substituted pyrazinecarboxylic acid 
esters have been previously reported to have in vitro activity against M. avium and M. 
kansasii as well as M. tuberculosis. Modification of both the pyrazine nucleus and the ester 
functionality was successful in expanding the antimycobacterial activity associated with 
PZA to include M. avium and M. kansasii, organisms usually not susceptible to 
pyrazinamide. In an attempt to understand the relationship between the activities of the 
esters and the needed biostability, quantitative structure-activity relationships (QSAR) 
were found (Fernandes et al., 2010). While POA cannot pass through mycobacterial cell 
walls due to its low lipophilicity, the esterification of POA is a suitable approach to 
increase the likelihood of its penetration into the resistant mycobacteria (Cynamon et al., 
1992; Cynamon et al., 1995). Thus series of POA esters were prepared and evaluated. 
PZA-resistant isolates became susceptible in vitro to pyrazinoic acid, and n-propyl 
pyrazinoate was the most promising candidate (see Fig. 5, structure V). Esters of POA 
appeared to circumvent the requirement for activation by mycobacterial amidase. The 
MICs of n-propyl pyrazinoate for M. tuberculosis isolates were lower than those of 
pyrazinoic acid. This may lead to a candidate compound with enhanced activity against 
both PZA-susceptible and PZA-resistant M. tuberculosis isolates suitable for clinical 
development (Cynamon et al., 1992; Speirs et al., 1995). However, efficacy studies in mice 
failed to show any antitubercular activity likely due to poor stability of the esters in 
plasma (Zhang & Mitchison, 2003). Another series of more lipophilic ester prodrugs (i.e. 
tetradecyl ester) were found to be active in concentrations 10-fold lower than those 
needed for PZA to kill sensitive M. tuberculosis and also have suitable stability in the 
presence of plasma (Simoes et al., 2009). These relationships are consistent with the 
observation that tert-butyl 5-chloropyrazine-2-carboxylate and 2-methyldecyl  
5-chloropyrazine-2-carboxylate are 100-fold more active than PZA against M. tuberculosis 
and exhibit serum stability 900-1000 times greater than the lead compounds in the series. 
Some 5-hydroxypyrazine-2-carboxylic acid derivatives (see Fig. 5, general structure VI) 
are up to 1000-fold more active against M. tuberculosis and other Mycobacterium strains 
than existing antituberculous agents (Bergmann et al., 1996); synthesis of compounds VI 
is important, because it is a building block for the synthesis of new antituberculous 
agents. 5-Hydroxypyrazine-2-carboxylic acid can be produced microbiologically by 
whole-cell biotransformation of 2-cyanopyrazine (Wieser et al., 1997). Various substituted 
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analogues of PZA with bioisosteric replacements of the carboxylic acid functionality were 
prepared. Thus 5-aroylpyrazine-2-carboxylic acid (see Fig. 5, general structure VII, 
Doležal et al., 2003) and arylsulfanylpyrazinecarboxylic acid (see Fig. 5, general structure 
VIII, Jampílek et al., 2007) derivatives were investigated as potential antitubercular 
agents. 
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Fig. 5. Structures of pyrazine-2-carboxylic acid derivatives. 
In order to find more active PZA derivatives, various PZA analogues were synthesized and 
assayed against M. tuberculosis (Yamamoto et al, 1995). In these experiments, four 
compounds showed high levels of antimycobacterial activities, not only bacteriostatic but 
also bactericidal, against M. tuberculosis as well as M. avium complex (MAC). These 
compounds, namely, pyrazinoic acid pivaloyloxymethyl ester, pyrazinoic acid n-octyl ester, 
pyrazinethiocarboxamide and N-hydroxymethylpyrazinethiocarboxamide, may warrant 
further examinations. 5-Chloropyrazine-2-carboxamide (see Fig. 6, structure IX) showed 
excellent in vitro activity against PZA-resistant strains of M. tuberculosis (Cynamon et al., 
1998). Therefore FAS I and/or FAS II were proposed as a target of this compound, i.e. this 
compound possesses a different mechanism of action (Boshoff et al., 2002). Due to this fact  
3-chloropyrazine-2,5-dicarbonitrile (see Fig. 6, structure X, Palek et al., 2008) and  
6-chloro-5-cyanopyrazine-2-carboxamide (see Fig. 6, structure XI, Dlabal et al., 1990; Zitko et 
al., 2011) and their derivatives were synthesized, and their noteworthy antimycobacterial 
activities were reported recently. 
3. Anti-Mycobacterium tuberculosis bioassays 
Several in vitro bioassays have been developed to evaluate antitubercular activity of 
chemical compounds. In most of these methods, Mycobacterium is cultured in various types 
of broth- and agar-based media. But, the main problems are long growth time  
(several weeks) and its pathogenicity, hence containment facilities are required. The 
common conditions for the anti-TB susceptibility evaluation are influenced by acid-base 
properties of medium (McDermott & Tompsett, 1954). For nearly two decades the 
radiometric BACTEC 460TB System provided the most rapid method for antimicrobial 
susceptibility testing (Siddiqi, 1992). 
The Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) was 
established in 1994 by the National Institute of Allergy and Infectious Diseases (a part of the 
National Institute of Health of the US Government) in order to encourage the discovery of 
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new antitubercular drugs. The program managed by Southern Research Institute 
(Birmingham, Alabama, USA) assisted commercial, academic and government laboratories 
worldwide in identifying new chemical classes of compounds for evaluation using in vitro 
and in vivo models. These screening activities have resulted in several promising agents that 
have reached advanced stages of testing. TAACF was providing a great service to mankind 
by way of screening thousands of compounds synthesized in research laboratories across 
the globe for activity against TB and related diseases. The TAACF program has ended in 
March 2010 (TAACF, 2010). This in vitro screening had several levels. 
N
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Fig. 6. Structures of chloropyrazine derivatives. 
3.1 In vitro bioassays (% of inhibition) 
The primary screening was conducted at 6.25 g/mL (or molar equivalent of the highest 
molecular-weight compound in a series of congeners) against M. tuberculosis H37Rv 
(ATCC 27294) in BACTEC 12B medium using the Microplate Alamar Blue Assay (MABA) 
(Collins & Franzblau, 1997). Compounds 1–91 and 104–115 were tested in the BACTEC 
460-radiometric system. In general, compounds effecting >90% inhibition in the primary 
screening (MIC <6.25 g/mL) were further evaluated. The results are presented in Tables 1, 
2 and 4. 
3.2 Primary screening (dose response): Determination of 90% inhibitory 
concentration (IC90 values) 
The initial screening was conducted against M. tuberculosis H37Rv (ATCC 27294) in 
BACTEC 12B medium using the Microplate Alamar Blue Assay (MABA) (Collins & 
Franzblau, 1997). Compounds 92-103 were tested in ten 2-fold dilutions; typically from 
100 µg/mL to 0.19 µg/mL. The IC90 is defined as the concentration effecting a reduction in 
fluorescence of 90% relative to controls. This value is determined from the dose-response 
curve using a curve-fitting programme. Any IC90 value of ≤10 µg/mL is considered "active" 
for antitubercular activity. For the results see Table 3. 
3.3 Secondary screening: Determination of mammalian cell cytotoxicity (CC50) 
The VERO cell cytotoxicity assay was done in parallel with the TB Dose Response assay. 
After 72 hours exposure, viability was assessed using Promega's Cell Titer Glo 
Luminescent Cell Viability Assay, a homogeneous method of determining the number of 
viable cells in culture based on quantification of the ATP present. Cytotoxicity was 
determined from the dose-response curve as the CC50 using a curve fitting program. 
Ultimately, the CC50 was divided by the IC90 to calculate an SI (Selectivity Index) value. SI 
values of ≥10 were considered for further testing (TAACF, 2010). The results are presented 
in Table 2. 
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4. Physico-chemical properties of prepared compounds 
It is generally admitted in drug research that the passage of molecules across cellular 
barriers increases with lipophilicity and that the most lipophilic compounds have the 
highest intestinal absorption. Most of the drugs behave in solution as weak acids, weak 
bases or sometimes as both weak acids and weak bases. 
4.1 Capacity factor k determination (log k and distributive parameters π) 
A Waters Alliance 2695 XE HPLC separation module and a Waters Photodiode Array 
Detector 2996 (Waters Corp., Milford, MA, USA) were used. A Symmetry® C18 5 μm, 
4.6250 mm (Waters Corp., Milford, MA, USA) chromatographic column was used. The 
HPLC separation process was monitored by Millennium32® Chromatography Manager 
Software, Waters 2004 (Waters Corp., Milford, MA, USA). A mixture of MeOH p.a. (70.0%) 
and H2O-HPLC – Mili-Q Grade (30.0%) was used as a mobile phase. The total flow of the 
column was 1.0 mL/min, injection volume 30 μL, column temperature 30 °C and sample 
temperature 10 °C. The detection wavelength of 223 nm was chosen. The KI methanolic 
solution was used for the dead time (tD) determination. Retention times (tR) were measured 
in minutes, capacity factors (k) were calculated. The calculated log k values of all compounds 
are shown in Tables 1, 3 and 4. 
The distributive parameters π characterizing lipophilicity of individual moieties substituted 
on the skeleton were calculated as the differences of determined capacity factor logarithms 
of individual unsubstituted and substituted compounds. The calculated π values of all 
substituents in the amide part of the molecule are shown in Tables 1, 3 and 4. 
4.2 Physico-chemical properties calculations (log P, log S, pKa) 
For calculation of the basic parameters the ACD/Labs software was used. The values of 
hydro/lipophilic properties expressed as log P were calculated by ACD/LogP DB; solubility 
data expressed as log S were calculated by ACD/LogS DB (aqueous log S at pH 7.4), and 
acid-base characteristics expressed as dissociation constants pKa were calculated by 
ACD/pKa DB. Results are shown in Tables 1, 3 and 4. 
5. Antimycobacterial evaluation of substituted pyrazinecarboxamides 
The amide function considered in this chapter is based on the bivalent moiety -CONH-, 
which can form centrosymmetric dimer pairs: (i) with another molecule of carboxamide 
(see Fig. 7, a) or (ii) with the carboxamide group of some peptide (see Fig. 7, b). Various 
compounds possessing -CONH- moiety as a bridging ligand between the heteroaromatic or 
basic part and the aromatic part of the molecule were found to inhibit the M. tuberculosis. 
The presented study deals with the synthesis of the series of amides prepared via 
anilinolysis of substituted pyrazinecarboxylic acid chlorides with alkylated, hydroxylated 
and/or halogenated anilines (see Section 5.1) or with substituted aminothiazoles 
(see Section 5.2). The aim of this work is to find the structure-activity relationships in the 
mentioned series, i.e. to continue studying the substituent variability influence on the 
biological activity, and to determine the importance of increased hydrophobic properties for 
biological evaluation of newly prepared substituted pyrazinecarboxamides. 
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Fig. 7. Possible formation of centrosymmetric dimer pairs of carboxamide group. 
5.1 Substituted N-phenylpyrazine-2-carboxamides 
An effective method that can lead to design of new drugs with higher or modified biological 
activity is analogy application. Pyrazine skeleton can be substituted by aliphatic, cyclic or 
hetero/aromatic substituents. Also hydrogens of amidic nitrogen can be substituted. It is 
important to note that an amidic bond (-CONH-) can mimic a peptide bond. This moiety can 
form hydrogen bonds to active sites of various enzymes, and therefore only one amide 
hydrogen should be substituted to maintain this bonding capability (namely by an aromatic 
(phenyl) or heteroaromatic ring in this series). This approach (radical analogy) provides 
multiple opportunities for further modifications; therefore a series of 115 carboxamides 
derived from pyrazine-2-carboxylic acid and various ring-substituted anilines and/or 
2-aminothiazoles was designed and prepared. These compounds were primarily designed 
as potential antimycobacterial compounds, but they also showed noteworthy antifungal 
activity. The assumption concerning binding to different enzymes through the amide moiety 
was confirmed, as the mentioned compounds considerably inhibited electron transport in 
photosystem PS 2 during photosynthesis in spinach chloroplasts, so they can be potentially 
used as herbicides (Doležal & Kráľová, 2011). 
The final compounds 1-103 were prepared by the anilinolysis of substituted 
pyrazinoylchlorides (Doležal et al., 1999, 2000, 2002, 2006b, 2007, 2008a, 2008b, 2009, 2010; 
their synthesis and structure are presented in Fig. 8 and in Tables 1 and 3). Their chemical 
structure, electronic parameters expressed as Hammett's σ parameter (Norrington et al., 
1975), hydrophobic parameters (experimentally determined log k, experimentally 
determined distributive parameters πPh for individual aniline substituents, log P calculated 
by ACD/LogP DB), solubility (log S calculated by ACD/LogS DB), dissociation constants 
(pKa calculated by ACD/pKa DB), antituberculotic inhibiting activity and structure-activity 
relationships (SAR) were studied.  
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Fig. 8. Synthesis and structure of substituted N-phenylpyrazine-2-carboxamides 1-103. 
The following was synthesized in preference: (i) compounds with lipophilic and/or 
electron-withdrawing substituents on the benzene moiety (R3), (ii) compounds with 
hydrophilic and/or electron-donating groups on the benzene part of the molecule (R3), and 
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finally (iii) compounds with a lipophilic alkyl chain (R2), i.e. tert-butyl (-C(CH3)3) and/or 
halogen (chlorine) substitution (R1) on the pyrazine nucleus. The data are presented in 
Tables 1 and 3. The substituents on the phenyl ring were selected according to the principles 
set by Topliss (Topliss & Costello, 1972). 
No. R1 R2 R3 
Inhib.
[%] 
σPh πPh log k log P log S pKa Ref. 
PZA see Fig. 1, structure I ** – – – -0.71±0.28 -0.76
13.91±0.50 
0.87±0.10 
** 
1 H H 3-CF3 99 0.43 0.19 0.5585 3.05±0.54 -3.23
11.36±0.70 
0.14±0.10 
-4.48±0.10 
b 
2 Cl (CH3)3C 4-OH 97 -0.37 -0.21 0.9236 3.15±0.95 -3.72
11.34±0.30 
9.50±0.70 
1.30±0.50 
-4.79±0.10 
f 
3 Cl (CH3)3C 2-OH 96 -0.09 -0.08 1.1148 4.04±0.69 -4.04
11.46±0.35 
8.52±0.35 
1.57±0.50 
-4.88±0.10 
f 
4 Cl (CH3)3C 3-CF3 95 0.43 0.19 1.5271 5.03±0.68 -5.10
9.44±0.70 
-0.25±0.10 
-4.87±0.10 
b 
5 Cl (CH3)3C 3-F 88 0.34 0.03 1.2974 3.20±0.71 -4.35
9.20±0.70 
-0.30±0.10 
-4.92±0.10 
d 
6 H H 4-CH3 86 -0.17 0.07 0.4595 2.70±0.50 -2.68
11.91±0.70 
0.80±0.50 
-4.27±0.10 
b 
7 Cl H 3-CF3 77 0.43 0.19 0.8362 3.44±0.67 -3.88
9.37±0.70 
-0.84±0.50 
b 
8 Cl (CH3)3C 3-OH 75 0.12 -0.19 0.9473 3.24±0.65 -3.76
10.54±0.10 
9.09±0.10 
-0.13±0.10 
-4.67±0.10 
f 
9 Cl H 4-CH(CH3)2 73 -0.15 0.37 0.9920 3.64±0.64 -3.90
9.88±0.70 
0.61±0.50 
d 
10 Cl (CH3)3C
4-OH-3,5-
Br 
72 0.41 0.50 1.8895 5.25±1.03 -5.34
8.84±0.70 
6.56±0.36 
-0.38±0.50 
a 
11 Cl (CH3)3C 3,5-CF3 72 0.86 0.51 1.8982 5.92±0.74 -5.95
8.90±0.70 
-0.40±0.10 
e 
12 Cl H 4-CH3 71 -0.17 0.07 0.7627 3.10±0.64 -3.34
9.92±0.70 
0.64±0.50 
b 
13 H (CH3)3C 3-F 71 0.34 0.03 0.9588 2.91±0.59 -3.75
9.87±0.70 
1.07±0.10 
-3.55±0.10 
d 
14 H (CH3)3C 4-CH(CH3)2 71 -0.15 0.37 1.3281 4.94±0.51 -4.51
10.62±0.70 
1.31±0.10 
-3.29±0.10 
d 
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No. R1 R2 R3 
Inhib.
[%] 
σPh πPh log k log P log S pKa Ref. 
15 Cl H 
4-OH-3,5-
Br 
69 0.41 0.50 1.1350 3.66±1.02 5.34 
8.76±0.70 
6.55±0.36 
-0.39±0.50 
a 
16 Cl H 4-Cl 65 0.23 0.16 0.8185 2.23±0.73 -3.37
9.04±0.70 
-0.53±0.50 
g 
17 Cl H 3,4-Cl 61 0.60 0.38 0.9950 3.60±0.81 -4.38
8.37±0.70 
-1.33±0.50 
a 
18 H (CH3)3C 4-CH3 61 -0.17 0.07 1.0222 4.40±0.52 -3.98
10.66±0.70 
1.32±0.10 
-3.29±0.10 
b 
19 H (CH3)3C
4-OH-3,5-
Br 
54 0.41 0.50 1.4758 4.96±0.95 -4.74
9.50±0.70 
6.64±0.36 
0.88±0.10 
-3.75±0.10 
a 
20 H (CH3)3C 3-OCH3 53 0.12 -0.02 0.9146 3.71±0.52 -3.71
10.19±0.70 
1.28±0.10 
-3.34±0.10 
a 
21 H (CH3)3C 4-COCH3 53 0.81 -0.06 0.8573 3.34±0.53 -3.92
10.12±0.70 
0.98±0.10 
-3.45±0.10 
h 
22 H (CH3)3C 4-OH 50 -0.37 -0.21 0.6779 2.86±0.87 -3.12
11.39±0.30 
9.64±0.26 
1.40±0.10 
-3.42±0.10 
f 
23 Cl H 4-F 44 0.06 0.05 0.7284 2.14±0.69 -3.29
8.89±0.70 
0.19±0.50 
b 
24 H (CH3)3C 3-OH 44 0.12 -0.19 0.7130 2.95±0.51 -3.15
10.79±0.70 
9.16±0.10 
1.24±0.10 
-3.30±0.10 
f 
25 H (CH3)3C 2,4-F 44 0.53 0.14 1.0992 2.99±0.68 -4.24
8.55±0.70 
0.90±0.10 
-3.73±0.10 
d 
26 H (CH3)3C 3-Br 39 0.39 0.21 1.1516 4.45±0.57 -4.28
9.98±0.70 
1.19±0.10 
-3.43±0.10 
e 
27 H H 2-CF3 31 – 0.30 0.6511 2.60±0.54 -3.07
11.14±0.70 
0.04±0.10 
-4.59±0.10 
b 
28 Cl (CH3)3C 2-OH-5-Br 30 0.30 0.17 1.5181 5.27±0.74 -4.92
10.80±0.48 
7.86±0.48 
0.73±0.50 
-4.94±0.10 
a 
29 Cl H 2-Br 28 0.71 0.40 1.0014 2.67±0.69 -3.47
8.98±0.70 
-0.83±0.50 
a 
30 Cl H 3-F 28 0.34 0.03 0.7135 1.61±0.70 -3.1 
9.13±0.70 
-0.65±0.50 
d 
31 Cl H 3-CH3 28 -0.07 0.07 0.7557 3.13±0.64 -3.35
9.92±0.70 
0.24±0.50 
e 
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No. R1 R2 R3 
Inhib.
[%] 
σPh πPh log k log P log S pKa Ref. 
32 H (CH3)3C 2-OH 28 -0.09 -0.08 0.8350 3.76±0.57 -3.44
11.51±0.35 
8.67±0.35 
1.63±0.50 
-3.51±0.10 
f 
33 Cl H 2-CF3 26 – 0.30 0.9102 3.00±0.67 -3.72
9.15±0.70 
-1.33±0.10 
b 
34 Cl (CH3)3C 2-Br 25 0.71 0.40 1.7673 4.26±0.70 -4.71
9.06±0.70 
-0.39±0.10 
a 
35 H (CH3)3C 4-F 25 0.06 0.05 0.9948 3.44±0.57 -3.94
9.63±0.70 
1.20±0.10 
-3.42±0.10 
b 
36 Cl (CH3)3C 3-CH3 24 -0.07 0.07 1.3288 4.71±0.65 -4.59
9.99±0.70 
0.25±0.50 
-4.57±0.10 
e 
37 Cl (CH3)3C 4-Cl 24 0.23 0.16 1.5015 3.82±0.78 -4.62
9.11±0.70 
-0.26±0.10 
-4.88±0.10 
g 
38 H (CH3)3C 3-CF3 23 0.43 0.19 1.1338 4.74±0.55 -4.50
10.11±0.70 
1.12±0.10 
-3.50±0.10 
b 
39 Cl (CH3)3C 3-OCH3 23 0.12 -0.02 1.2148 4.00±0.65 -4.31
9.53±0.70 
-0.09±0.10 
-4.70±0.10 
a 
40 H H 2-OH-5-Cl 22 0.28 0.12 0.4541 3.71±0.75 -3.23
11.45±0.70 
8.12±0.48 
0.93±0.50 
-4.67±0.10 
f 
41 H (CH3)3C 2-Br 22 0.71 0.40 1.4057 3.97±0.57 -4.11
9.72±0.70 
0.98±0.10 
-3.64±0.10 
a 
42 Cl (CH3)3C 4-COCH3 22 0.81 -0.06 1.1676 3.63±0.66 -4.52
9.46±0.70 
-0.39±0.10 
-4.82±0.10 
h 
43 Cl (CH3)3C 2,4-F 21 0.53 0.14 1.4793 3.28±0.78 -4.84
7.88±0.70 
-0.05±0.50 
d 
44 Cl (CH3)3C 3-Br 20 0.39 0.21 1.5502 4.73±0.70 -4.88
9.32±0.70 
-0.18±0.10 
-4.80±0.10 
e 
45 Cl H 3-Br 19 0.39 0.21 0.8452 3.15±0.69 -3.64
9.24±0.70 
-0.75±0.50 
e 
46 H (CH3)3C 2-OCH3 18 0.00 0.04 0.9928 4.17±0.56 -3.87
10.02±0.70 
1.28±0.10 
-3.34±0.10 
e 
47 Cl (CH3)3C 2-OH-5-Cl 17 0.28 0.12 1.4529 5.69±0.87 -5.14
10.93±0.48 
7.99±0.48 
0.78±0.50 
f 
48 Cl H 2-Cl-5-OH 15 0.79 0.11 0.7801 1.78±0.69 -3.06
10.09±0.18 
8.60±0.70 
-1.09±0.50 
b 
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No. R1 R2 R3 
Inhib.
[%] 
σPh πPh log k log P log S pKa Ref. 
49 H (CH3)3C 3,4-Cl 15 0.60 0.38 1.3395 4.90±0.78 -5.01
9.11±0.70 
0.83±0.10 
-3.80±0.10 
a 
50 Cl (CH3)3C 4-F 15 0.06 0.05 1.3238 3.72±0.70 -4.54
8.97±0.70 
0.19±0.50 
-4.79±0.10 
b 
51 H H 3-Cl 14 0.37 0.14 0.4914 3.24±0.65 -3.22
11.24±0.70 
0.09±0.10 
-4.53±0.10 
g 
52 Cl H 3-Cl 14 0.37 0.14 0.7864 3.63±0.77 -3.88
9.24±0.70 
-0.71±0.50 
g 
53 Cl H 4-OH 14 -0.37 -0.21 0.5587 1.56±0.95 -2.46
11.33±0.30 
9.43±0.70 
1.30±0.50 
f 
54 Cl H 3-OH 13 0.12 -0.19 0.5758 1.65±0.64 -2.49
10.54±0.10 
9.08±0.10 
-0.17±050 
f 
55 Cl (CH3)3C 2,6-CH3 13 0.20 0.20 1.5286 4.23±0.66 -4.56
10.00±0.70 
1.45±0.50 
-4.74±0.10 
e 
56 Cl H 3,5-CF3 12 0.86 0.51 1.1384 4.33±0.71 -4.77
8.82±0.70 
-1.39±0.10 
e 
57 Cl H 4-COCH3 11 0.81 -0.06 0.6548 2.04±0.65 -3.29
9.38±0.70 
-1.37±0.10 
h 
58 Cl H 3,5-OCH3 11 0.24 0.08 0.7701 2.70±0.66 -3.32
8.99±0.70 
-0.43±0.50 
a 
59 H (CH3)3C 3-CH3 11 -0.07 0.07 1.0191 4.43±0.52 -3.99
10.65±0.70 
1.41±0.10 
-3.20±0.10 
e 
60 H (CH3)3C 3,5-CF3 10 0.86 0.51 1.4861 5.63±0.62 -5.35
9.56±0.70 
0.96±0.10 
-3.66±0.10 
e 
61 H H 3,4-Cl 8 0.60 0.38 0.7162 3.20±0.78 -3.72
10.36±0.70 
-0.15±0.10 
-4.78±0.10 
g 
62 H (CH3)3C 2-CF3 7 – 0.30 1.2522 4.30±0.55 -4.34
9.89±0.70 
1.02±0.10 
-3.61±0.10 
b 
63 H (CH3)3C 2-OH-5-Cl 6 0.28 0.12 1.0803 5.40±0.75 -4.53
10.97±0.48 
8.14±0.48 
0.94±0.10 
-3.69±0.10 
f 
64 Cl (CH3)3C 2-CF3 6 – 0.30 1.6560 4.58±0.68 -4.94
9.22±0.70 
-0.35±0.10 
4.97±0.10 
b 
65 H (CH3)3C 3,5-OCH3 5 0.24 0.08 1.0286 4.00±0.54 -3.93
9.73±0.70 
1.16±0.10 
-3.46±0.10 
a 
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No. R1 R2 R3 
Inhib.
[%] 
σPh πPh log k log P log S pKa Ref. 
66 H H 4-Cl 4 0.23 0.16 0.4987 1.84±0.60 -2.72
11.03±0.70 
0.13±0.10 
-4.49±0.10 
g 
67 Cl (CH3)3C 4-CH(CH3)2 4 -0.15 0.37 1.7297 5.22±0.65 -5.10
9.96±0.70 
0.62±0.50 
-4.66±0.10 
d 
68 Cl H 3-OCH3 2 0.12 -0.02 0.6671 2.41±0.64 -3.08
9.45±0.70 
-0.17±0.50 
a 
69 H (CH3)3C 2,6-CH3 2 0.20 0.08 1.1387 3.94±0.52 -3.96
10.67±0.70 
1.51±0.50 
-3.37±0.10 
e 
70 Cl H 2,4-F 1 0.53 0.14 0.8164 1.69±0.73 -3.59
7.81±0.70 
-0.05±0.50 
d 
71 H H 4-F 0 0.06 0.05 0.4416 * * * b 
72 H H 2,6-Cl 0 1.34 0.32 0.6656 * * * g 
73 H H 2-Cl-5-OH 0 0.79 0.11 0.4527 * * * b 
74 Cl H 2-OH 0 -0.09 -0.08 0.6447 * * * f 
75 Cl H 2-CH3 0 0.10 0.13 0.7774 * * * e 
76 Cl H 2,6-CH3 0 0.20 0.20 0.8451 * * * e 
77 Cl H 2,6-Cl 0 1.34 0.32 0.9696 * * * g 
78 Cl H 2-OH-5-Br 0 0.30 0.17 0.8305 * * * a 
79 H (CH3)3C 2-CH3 0 0.10 0.13 1.0984 * * * e 
80 H (CH3)3C 3-Cl 0 0.37 0.14 1.0996 * * * g 
81 H (CH3)3C 4-Cl 0 0.23 0.16 1.1043 * * * g 
82 H (CH3)3C 2-OH-5-Br 0 0.30 0.17 1.1070 * * * a 
83 H (CH3)3C 2-Cl-5-OH 0 0.79 0.11 1.0654 * * * b 
84 H (CH3)3C 2,6-Cl 0 1.34 0.32 1.2802 * * * g 
85 Cl (CH3)3C 2-CH3 0 0.10 0.13 1.4772 * * * e 
86 Cl (CH3)3C 3-Cl 0 0.37 0.14 1.4896 * * * g 
87 Cl (CH3)3C 4-CH3 0 -0.17 0.07 1.3305 * * * b 
88 Cl (CH3)3C 2-Cl-5-OH 0 0.79 0.11 1.4335 * * * b 
89 Cl (CH3)3C 2,6-Cl 0 1.34 0.32 1.6631 * * * g 
90 Cl (CH3)3C 3,4-Cl 0 0.60 0.38 1.7563 * * * a 
91 Cl (CH3)3C 3,5-OCH3 0 0.24 0.08 1.3564 * * * a 
Table 1. Structures, antimycobacterial evaluation (% of inhibition), logarithms of capacity 
factors (log k), calculated lipophilicity (log P), solubility (log S) and acid-base properties 
(pKa) of compounds 1-91 in comparison with the standard (PZA). Electronic parameters are 
expressed as Hammett's σ parameter (Ref. Norrington et al., 1975). Compounds are ordered 
according to their decreasing inhibiting activity (Ref Doležal et al., 2008(a), 1999(b), 2000(c), 
2006b(d), 2002(e), 2010(f); Kutilová, 2007(g)). *MIC = 16-50 μg/mL at pH 5.5 (Ref. McDermott & 
Tompsett, 1954) or MIC = 100 μg/mL at pH 6.0 by the BACTEC method (Ref. Siddiqi, 1992). 
**ACD values were not calculated for activity 0%. 
It can be drawn from Table 1 that growth inhibition of M. tuberculosis strain H37Rv at 
6.25 μg/mL ranged 0-99%: 0% activity was shown by 21 compounds, 1-49% activity was 
possessed by 48 compounds and 50-99% activity was shown by 22 compounds, which will 
be primarily discussed below. According to pyrazine substitution, all compounds in Table 1 
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can be divided into 4 groups: (i) series I – unsubstituted pyrazine core; (ii) series II – 
pyrazine substituted by chlorine in position 6 (R1 = Cl); (iii) series III – pyrazine substituted 
by tert-butyl in position 5 (R2 = tert-Bu); (iv) series IV – pyrazine substituted by chlorine in 
position 6 and by tert-butyl in position 5 (R1 = Cl and R2 = tert-Bu). When the compounds 
with the activity above 50% are divided into the individual series, series I contains 
2 compounds with average activity 93%, series II contains 6 compounds with average 
activity 69%, series III contains 7 compounds with average activity 59%, and series IV 
contains 7 compounds with average activity 85%. According to this analysis it can be stated 
that the most favourable is C(5) and C(6) disubstitution of pyrazine R1 = Cl and R2 = tert-Bu, 
i.e. series IV, followed by unsubstituted pyrazine (series I) and C(6) monosubstitution R1 = Cl 
(series II). The least favourable is C(5) monosubstitution of pyrazine by tert-Bu, i.e. series III. 
Particular substituents on benzenes can be ordered according to their efficiency. Benzene 
substitutions 2,6-Cl, 2-X-5-OH, 2-OH-5-X, 4-X, 3-alkyl, 3-X and 2-CH3 (X = halogen) appear 
to be the least advantageous. The most advantageous is substitution 3-CF3 followed by 
4-CH3, 4-CH(CH3)2, 3-F and 3,5-CF3. In all cases this is substitution in meta and/or para 
positions, mostly by lipophilic substituents (experimentally determined distributive 
parameters πPh = 0.03–0.51 with optimum πPh = 0.07–0.19). Moieties meta-CF3 and 3-F are 
electron-withdrawing substituents with σ = 0.43 or σ = 0.34, whereas substituents 4-CH3 or 
4-CH(CH3)2 with σ = -0.17 or σ = -0.15 are significantly electron-donating. 
Substituents with hydrophilic groups on the benzene part of the molecule did not show any 
inhibiting activity. However, it is worth mentioning that only in series IV substitutions 
4-OH and 2-OH are the most favourable, thus with markedly hydrophilic πPh = -0.21 or 
πPh = -0.08 as well as electron-donating substituents with σ = -0.37 or σ = -0.09. Generally, it 
can be stated that the optimum lipophilicity value range is log k = 0.6–1.5 or log P = 1.6–6.8, 
but as regards antitubercular activity (see Table 1), it can be concluded that lipophilicity is 
only a secondary parameter, facilitating penetration through highly lipophilic mycobacterial 
wall. According to Table 1 and log S (solubility values) it can be stated that with lower 
aqueous solubility (lower value of log S), antimycobacterial inhibition decreases, except 
series I. The dissociation constant pKa is also a very important parameter. According to 
Table 1 it can be generally stated that higher pKa (basicity close to PZA) supports higher 
antitubercular activity. 
The selected anilides 1-4 that expressed the highest antitubercular activity are illustrated in 
Table 2. As mentioned in Section 3, the most effective compounds were tested for their 
cytotoxicity, and subsequently the Selectivity Index, i.e. the ratio of cell cytotoxicity (CC50) to 
activity (MIC) was obtained. It can be drawn from Table 2 that compound 1 from series I 
showed the highest inhibition activity and also minimal toxicity. According to MIC it can be 
stated that compound 4 seems to be more effective than compound 1, but unfortunately its 
determined SI value was not as favourable as in the case of compound 1. Based on these 
observations it can be concluded that N-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide 
(1) can be considered to be a promising agent. 
Compounds 92-103 mentioned in Table 3 showed a broad spectrum of antitubercular 
activity, but these activities are not expressed in concrete numbers, unlike inhibition 
activities in Table 1, therefore no thorough structure-activity relationships could be 
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established. Nevertheless, with regard to this fact, it is possible to propose at least general 
SAR based on the above-discussed observations. 
In terms of PZA substitution series IV is the most advantageous, and the most favourable 
substitution on the benzene ring is 3-I-4-CH3. All effective compounds listed in Table 2 
possess high lipophilicity; the most active compound 92 has log k about 1.9 or log P about 6, 
which enables good penetration to mycobacterial cell. Calculated solubility is relatively low, 
but under the testing conditions it was probably sufficient, so there was no precipitation 
during testing. 
  
No. R1 R2 R3 
Inhib.
[%] 
MIC 
(g/mL) 
CC50 
(g/mL) SI Ref. 
1 H H 3-CF3 99 6.25 >62.5 >10 a 
2 Cl (CH3)3C 4-OH 97 <12.5 - - b 
3 Cl (CH3)3C 2-OH 96 <12.5 - - b 
4 Cl (CH3)3C 3-CF3 95 3.13 >10 >3.2 a 
Table 2. Structures, primary antimycobacterial evaluation (% of inhibition), actual minimum 
inhibitory concentrations (MIC), cytotoxicity (CC50), and selectivity indices (SI) of 
compounds 1-4 (Ref. Doležal et al., 2008(a), 1999(b)). 
No. R1 R2 R3 
IC90 
[µg/mL] 
σPh πPh log k log P log S pKa 
PZA see Fig. 1, structure I >20 * – – – -0.71±0.28 -0.76 
13.91±0.50 
0.87±0.10 
92 Cl (CH3)3C 3-I-4-CH3 0.819 0.18 0.56 1.9783 6.10±0.71 -5.42 
9.43±0.70 
-0.11±0.50 
-4.92±0.10 
93 Cl (CH3)3C 4-CF3 20.703 0.74 0.23 1.5611 4.39±0.68 -4.87 
9.27±0.70 
-0.41±0.10 
94 H H 3-I-4-CH3 69.099 0.18 0.56 0.8118 4.12±0.58 -3.56 
11.35±0.70 
0.10±0.10 
-4.53±0.10 
95 H H 4-CF3 >100 0.74 0.23 0.6220 2.41±0.54 -3.00 
11.19±0.70 
-0.02±0.10 
-4.63±0.10 
96 H H 
2-Br-3-
CH3 
>100 0.64 0.63 0.8784 3.22±0.57 -3.32 
10.98±0.70 
0.17±0.10 
-4.45±0.10 
97 Cl H 4-CF3 >100 0.74 0.23 0.8536 2.81±0.67 -3.65 
9.20±0.70 
-1.39±0.10 
98 Cl H 
2-Br-3-
CH3 
>100 0.64 0.63 1.2118 3.62±0.70 -3.98 
8.98±0.70 
-0.65±0.50 
99 Cl H 3-I-4-CH3 >100 0.18 0.56 1.1529 4.52±0.70 -4.21 
9.35±0.70 
-0.11±0.50 
100 H (CH3)3C 4-CF3 >100 0.74 0.23 1.1606 4.11±0.55 -4.27 
9.93±0.70 
0.96±0.10 
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No. R1 R2 R3 
IC90 
[µg/mL] 
σPh πPh log k log P log S pKa 
-3.65±0.10 
101 H (CH3)3C 3-I-4-CH3 >100 0.18 0.56 1.5766 5.82±0.59 -4.82 
10.09±0.70 
1.08±0.10 
-3.55±0.10 
102 H (CH3)3C
2-Br-3-
CH3 
>100 0.64 0.63 1.6327 4.92±0.59 -4.60 
9.72±0.70 
1.15±0.10 
-3.47±0.10 
103 Cl (CH3)3C
2-Br-3-
CH3 
>100 0.64 0.63 2.0821 5.20±0.71 -5.19 
9.06±0.70 
-0.22±0.10 
-4.84±0.10 
Table 3. Structures, antimycobacterial evaluation (% of inhibition), logarithms of capacity 
factors (log k), calculated lipophilicity (log P), solubility (log S) and acid-base properties 
(pKa) of compounds 92-103 in comparison with the standard (PZA). Electronic parameters 
are expressed as Hammett's σ parameter (Ref. Norrington et al., 1975). Compounds are 
ordered according to their decreasing inhibiting activity (Ref. Doležal et al., 2009). 
*MIC = 16-50 μg/mL at pH 5.5 (Ref. McDermott & Tompsett, 1954) or MIC = 100 μg/mL at 
pH 6.0 by the BACTEC method (Ref. Siddiqi, 1992). 
According to pKa these compounds are little less basic than PZA, which results in lower 
ionizability and higher penetration to the cell. Both types of active anilides have unsubstituted 
C´(2) position of benzene, which is also very important for easy anilide hydrolysis and release 
of active POA. It can be assumed that antimycobacterial activity is dependent on balanced 
lipo/hydrophilic properties and ionizability tending to the PZA value, but also it is strongly 
influenced by the facility of anilide hydrolysis to acid, which is facilitated by a free ortho 
position of the benzene ring and electron-withdrawing effect of substituents. 
5.2 Substituted N-(thiazol-2-yl)pyrazine-2-carboxamides 
A unique series of ring-substituted N-(thiazol-2-yl)pyrazine-2-carboxamides 104-115 is 
shown in Fig. 9. This series was prepared by the same method as used for substituted 
N-phenylpyrazine-2-carboxamides 1-103. Their physico-chemical properties and their 
inhibition of M. tuberculosis H37Rv at 6.25 μg/mL are listed in Table 4. It can be concluded 
that contrary to benzene analogues, tert-Bu (series III) or Cl+tert-Bu (series IV) is more 
advantageous than PZA substituent. The substitution by methyl in position 5 of the 
2-aminothiazole ring is unambiguously the most advantageous. The activity of the most 
active compound 104 is comparable with the activity of compound 18; but in general the 
series 5-CH3 (104, 105, 112, 113) possesses lower activity than 4-CH3 anilides (6, 12, 18, 87). 
5-Methylthiazolyl pyrazinecarboxamides expressed higher effect than 3-CH3 (31, 36, 59) and 
N
N
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R2
SOCl2
N
N
Cl
O
-HCl
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N
N
N
H
O
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Fig. 9. Synthesis of substituted N-(thiazol-2-yl)pyrazine-2-carboxamides 104-115. 
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also than 2-CH3 (75, 79, 85) anilides. In comparison with anilide analogues, 2-aminothiazoles 
possess little higher lipophilicity, lower solubility but considerably lower basicity, which in 
combination with heteroatoms of a thiazole moiety presumably influences the facility of 
hydrolysis ability and consequently, the resulting activity. Experimentally determined 
distributive parameters πTh for methylthiazolyl substituents are presented in Table 4. 
 
No. R1 R2 R3 Inhib. [%] πTh log k log P log S pKa 
PZA see Fig. 1, structure I ** – – -0.71±0.28 -0.76 
13.91±0.50 
0.87±0.10 
104 H (CH3)3C 5-CH3 65 0.14 1.0670 4.50±0.28 -4.66 
4.35±0.70 
1.98±0.10 
-0.67±0.10 
105 Cl (CH3)3C 5-CH3 61 0.14 1.4425 5.23±0.36 -5.29 
3.69±0.70 
1.77±0.10 
-2.04±0.10 
106 Cl (CH3)3C 4-CH3 52 0.12 1.4174 5.22±0.36 -5.29 
3.69±0.70 
1.80±0.10 
-2.04±0.10 
107 H (CH3)3C H 47 0 0.8987 4.20±0.27 -4.44 
4.35±0.70 
1.50±0.10 
-0.68±0.10 
108 Cl (CH3)3C H 42 0 1.2282 4.93±0.36 -5.08 
3.69±0.70 
1.28±0.10 
-2.05±0.10 
109 H (CH3)3C 4-CH3 35 0.12 1.0446 4.49±0.28 -4.65 
4.35±0.70 
2.01±0.10 
-0.67±0.10 
110 Cl H H 32 0 0.6064 3.34±0.27 -4.09 
3.61±0.70 
1.26±0.10 
-3.03±0.10 
111 Cl H 4-CH3 21 0.12 0.7068 3.63±0.28 -4.29 
3.62±0.70 
1.78±0.10 
-3.02±0.10 
112 Cl H 5-CH3 15 0.14 0.7213 3.64±0.28 -4.29 
3.62±0.70 
1.74±0.10 
-3.02±0.10 
113 H H 5-CH3 10 0.14 0.6193 2.80±0.27 -3.58 
5.61±0.70 
1.96±0.10 
-1.65±0.10 
114 H H H 0 0.00 0.5565 * * * 
115 H H 4-CH3 0 0.12 0.6112 * * * 
Table 4. Structures, antimycobacterial evaluation (% of inhibition), logarithms of capacity 
factors (log k), calculated lipophilicity (log P), solubility (log S) and acid-base properties 
(pKa) of substituted N-(thiazol-2-yl)pyrazine-2-carboxamides 104-115 in comparison with 
the standard (PZA). Electronic parameters are expressed as Hammett's σ parameter (Ref. 
Norrington et al., 1975). Compounds are ordered according to their decreasing inhibiting 
activity (Ref. Doležal et al., 2006b). *MIC = 16-50 μg/mL at pH 5.5 (Ref. McDermott & 
Tompsett, 1954) or MIC = 100 μg/mL at pH 6.0 by the BACTEC method (Ref. Siddiqi, 1992). 
**ACD values were not calculated for activity 0%. 
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Based on the above-mentioned results and discussion, it can be concluded that for high 
antitubercular activity C(5) and C(6) disubstitution of the pyrazine ring by lipophilic moieties 
is advantageous. Substitution of amidic hydrogen by ring-substituted anilines is more 
advantageous than by heteroaromatics, for example substituted pyrazine-2-carboxylic acid 
thiazol-2-ylamides showed only medium or moderate activity, and ring-substituted 
pyrazine-2-carboxylic acid pyridin-2-ylamides (non-mentioned in this chapter) did not 
express any antimycobacterial activity (Osička, 2003). High antitubercular efficiency 
requires substitution in para or preferentially in meta position of benzene, not in ortho 
position. Two combinations of substituents seem to be favoured: (i) lipophilic together with 
electron-withdrawing effect (3-CF3, 3-F) or (ii) expressively hydrophilic together with 
electron-donating effect (phenolic moiety), C(5) and C(6) disubstituted lipophilic pyrazine 
being strongly needed for the phenolic type of substituents. The same as PZA, the discussed 
amides are prodrugs that possess modified absorbency/permeability due to substitution, 
and after penetration through mycobacterial wall the amides are probably hydrolyzed by 
intracellular amidase to POA. The sufficient chemical stability of the mentioned compounds 
in slightly acidic environment used in testing is important for high antitubercular activity as 
well as subsequent facile hydrolysis by mycobacterial amidase. It seems that electron-
withdrawing substituents in meta and/or para positions provide adequate stability to the 
amidic bond and simultaneously do not protect this bond against the attack of amidase. No 
primary physico-chemical parameter that would obviously influence antitubercular 
inhibitory activity of the discussed substituted pyrazine-2-carboxamides was found. Apart 
from the balanced combination of secondary parameters (e.g. lipophilicity, solubility, 
substituent electronic parameters), a high enzymatic hydrolysis rate seems to be 
fundamental for rapid acidification of mycobacterial cytoplasm (by POA) or inhibition of 
some other cellular vital enzymatic systems by means of generated reactive intermediates  
(e.g. aminophenols, fluorinated anilines). 
6. Future research 
In the recent past, drug discovery efforts shifted towards the drug design based on docking 
studies. These docking computational techniques allow investigating the possible binding 
modes of a substrate to a given receptor, enzyme or another binding site and consequently 
determining and identifying the precise or different mechanism of action of both PZA and 
its derivatives, e.g. 5-chloropyrazine-2-carboxamide (IX) and similar compounds. Therefore 
the priority is to isolate the enzymes (from M. tuberculosis and subsequently from cells of 
other Mycobacterial strains) responsible for metabolization/activation of PZA and other 
enzymes that can be influenced by POA generation, e.g. FAS I, FAS II, etc. After isolation 
and determination of 3D structure by X-Ray structural analysis, it will be needed to 
crystallize enzymes with PZA and other PZA derivatives, determine 3D structures of these 
complexes and develop 3D-pharmacophore for systematic virtual screening based on this 
process. Then it will be possible to evaluate all PZA-like derivatives based on their virtual 
binding simulation and to carry out their evaluation using a large set of distance-based 
topological indices. In addition, various molecular descriptors can be used. 
As most pyrazine derivatives seem to be prodrugs and their activity is strongly dependent 
on the rate of hydrolysis to POA, further in vitro experiments with isolated enzymes should 
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be focused on determination of the hydrolysis rate. Also compounds of interest will be 
subject to in vivo studies for determination of their efficacy against murine M. tuberculosis. 
7. Conclusion 
PZA is a cornerstone drug of current TB therapy and emerged as an important building block 
for regimens with promise to shorten TB treatment. PZA is a prodrug which must be activated 
by the M. tuberculosis enzyme pyrazinamidase within the bacterium in order to exert its 
antitubercular activity. The project was focused on discovery of PZA analogues with PZA-like 
efficiency characteristics along with improved potency and increased safety. The main task 
was search for new antimycobacterial pyrazines – structure analogues of PZA. In summary, 
115 compounds were synthesized and screened for their antimycobacterial activity in the 
project. Chemical synthesis was followed by structure confirmation, experimental lipophilicity 
determination (log k) and theoretical lipophilicity calculation (log P). Biological evaluation 
comprised of antimycobacterial activity screening as the main task. This biological part of the 
project was successfully implemented in co-operation between TAACF, Southern Research 
Institute, Birmingham, USA, and the Faculty of Pharmacy in Hradec Králové, Charles 
University in Prague, Czech Republic, in years 1996—2009. The most active compounds are 
presented (see Tables 1-4) and discussed. Several very potent compounds (1-4, 92, 93) were 
discovered. The compounds relieved into level 2 testing underwent MIC and CC50 
determination followed by Selectivity Index calculation (SI, ratio of measured CC50 to MIC). To 
be relieved to level 3 (in vivo screening) the compound had to exhibit SI>10. Only one of the 
presented structures, N-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide (1) was relieved to 
level 3. The in vivo screening of compound 1 was not finished yet. The results of this project 
could be a very good starting point for the advanced drug design and development of new 
antituberculous agents based on pyrazine. 
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